Skip to content

Marine n-3 fatty acids and cardiovascular disease

Published: October 18, 2026Updated: October 18, 2026

Manson JE, Cook NR, Lee IM

New England Journal of Medicine · 2019

This randomized controlled trial evaluates the intervention under study in relation to the primary clinical outcome. Includes 25,871 participants. Evidence level: Ib.

Quick summary

循证研究:Omega-3 心血管结局研究

Medically reviewed by WellAlly Editorial TeamLast reviewed October 18, 2026Editorial policy

Key facts at a glance

DOI
10.1056/NEJMoa1205409
PMID
30415628
Journal
New England Journal of Medicine
Year
2019
Study type
rct
Evidence level
Ib
Sample size
25871
Intervention
EPA+DHA 1g/天 vs 安慰剂
Primary outcome
主要心血管事件
Open access
false

Study Overview

This randomized controlled trial enrolled 25,871 participants and examined the primary clinical outcome.

Key Findings

Results regarding the primary clinical outcome are presented.

Clinical Conclusions

See original publication for detailed findings. Evidence level: Ib.

Abstract

"This randomized controlled trial enrolled 25,871 participants, investigating the effects of EPA+DHA 1g/天 vs 安慰剂 on 主要心血管事件.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed October 18, 2026. · Read our editorial policy

More rct studies

View all